Replies to post #11171 on Cytodyn Inc (CYDY)

[pearsby09]

That is a little disconcerting. They have their minds set on DMD..miles away from HIV. Perhaps this is the disturbance that CRIO could not lure via HIV. Exon 51 has been burdened by third party reimbursement, due to an AA fast tract approval process. Due to questionable efficacy parameters and a very low "N" (still fulfilling FADASIA Criteria/Requirements) Third Party Insurers are very reticent to provide full Reimbursement (Exon 51). SRPT does have a pipeline of EXON skipping candidates..And GILD may be perusing Exon 53 and others...Unfortunately, not in the HIV pathway.